Carregant...

4CPS-142 Analysis of prescribing and clinical outcomes of vedolizumab treatment in a university care hospital

BACKGROUND: Vedolizumab became available in mid-2014 for the treatment of moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). The Spanish Drug Agency provided a Therapeutic Positioning Report about the clinical recommendation in the use of vedolizumab and its public funds. PURPOSE:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Hosp Pharm
Autors principals: Sanchez, E, Yañez, D, Carrion, IM, Montero, O, Martin, CB
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535458/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.233
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!